China approved the world’s first solid tumor CAR-T therapy. When will the US follow?
Biotech
Summary
CAR-T cell therapy has flourished since it was first used in 2010, leading to eight approved medicines for different blood cancers. But adapting the powerful technique, which involves engineering a patient’s own T cells to fight cancer, to solid tumors has proven a vexing challenge.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For China, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketChina
- ImpactMedium (56/100)
- SignalNews